Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylephrine is a selective alpha-1 adrenergic receptor agonist used primarily as a decongestant for the relief of nasal discomfort caused by colds and allergies. It is also indicated for sinus congestion and pressure. In addition to its use as an oral or nasal decongestant in over-the-counter products (such as Sudafed PE), phenylephrine is administered intravenously to manage hypotension during anesthesia and topically or ophthalmically to induce mydriasis (pupil dilation) or relieve eye redness. Its mechanism of action involves direct stimulation of alpha-1 adrenergic receptors on vascular smooth muscle leading to vasoconstriction; this reduces swelling in the nasal passages and increases blood pressure when given systemically[1][3][4][5]. Phenylephrine exhibits minimal beta-adrenergic activity[4]. It does not treat the underlying cause of symptoms but provides symptomatic relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylephrine.